WeMed Medical Launches First Multi-Center Clinical Study of Its Interventional Robot

WeMed Medical Officially Launches Multi-Center Clinical Study of RoboVisionaryA Endovascular Robotic System at the Shanghai World Expo Center

Marking the first post-market, multi-center clinical study of a domestically developed interventional robot, WeMed Medical continues to lead in intelligent diagnostics and treatment with its cutting-edge interventional robotics technology.

Multi-Center Study: Setting a New Benchmark for the Clinical Application of Endovascular Robotic Systems

Amid the growing convergence of digitalization and precision medicine, interventional surgical robots are emerging at the forefront of global medical technology innovation. The RoboVisionaryA project brings this vision into reality.

While current endovascular robotic systems serve as operator-controlled tools that significantly reduce radiation exposure and enhance the performance of complex procedures, artificial intelligence is poised to transform the field even further.

Future interventional robots will evolve into cognitive partners, capable of providing clinical decision support. Trained on vast datasets, these systems will master intricate techniques-such as identifying optimal wire navigation paths for chronic total occlusions (CTOs)-and may eventually exceed human capabilities in certain tasks.

The advancement of interventional surgical robotics is an unstoppable trend. Just as steam locomotives once outpaced horses during the Industrial Revolution, today's early robotic systems may still face limitations-but their eventual maturity is inevitable.

Now is the time to embrace this evolution. We must work together to accelerate the development of interventional robotic technology.

Interventional robotics will become a foundational productivity tool. I am confident that one day, this technology will evolve into a ubiquitous platform-one we look back on as transformative.

The study will be conducted in multiple phases, with the initial phase jointly launched by top-tier hospitals in China. It aims to rigorously evaluate the clinical efficacy and safety of robotic-assisted interventional procedures through large-scale, standardized data collection-ultimately providing high-quality, evidence-based insights for the industry.

Leading experts from China's premier hospitals gathered to officially launch the landmark RoboVisionaryA multi-center clinical study project.

Technological Breakthrough: From Manual Operation to Intelligent Control

At the heart of the program is WeMed Medical's ETcath200 Endovascular Robotic System, which marks a shift from manual techniques to intelligent control. It integrates multi-modal image fusion and haptic feedback to enhance surgical precision.

The system's proprietary Hand-Eye-Brain collaborative platform-featuring innovative multi-modal fusion technology-allows physicians to command a broader visual field through real-time HD imaging while experiencing tactile feedback that replicates real surgical resistance.

But the project's ambitions go further. As emphasized during the expert panel discussion:
"Future 5G/6G integration will empower interventional robotics to break physical barriers, enabling two-way transformation-democratizing specialist expertise while strengthening grassroots clinical capabilities."

This vision strongly resonated with participants, who agreed that interventional robotics will drive a shift from localized, organ-specific therapies toward integrated systemic treatments. Future advancements will accelerate along three major dimensions: intelligence-driven precision, remote accessibility, and more equitable patient access.

As the first NMPA-accelerated interventional robotic system in China, WeMed Medical's platform reflects a high level of technical maturity. This multi-center clinical initiative will foster expert collaboration and advance the convergence of AI and robotics in interventional medicine.